Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06365060 · ClinicalTrials.gov registry record
Screening for AL Amyloidosis in Smoldering Multiple Myeloma
A clinical trial of Smoldering Multiple Myeloma, sponsored by Tufts Medical Center.
- Recruiting
- Registry status
- 400
- Enrollment target
- 13
- Study locations
NCT06365060: Recruiting study of Smoldering Multiple Myeloma, sponsored by Tufts Medical Center.
NCT06365060 is a study of Smoldering Multiple Myeloma that is actively recruiting participants, run by Tufts Medical Center. The registered enrollment target is 400 participants, below the 780-participant average among 20 other Smoldering Multiple Myeloma trials with a reported enrollment target (49% lower). The trial reports 13 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06365060, a study of Smoldering Multiple Myeloma, is actively recruiting participants, sponsored by Tufts Medical Center.
- RECRUITING
- Registry status
- 400 participants
- Enrollment target
- 13
- Study locations
Study Summary
In this multicenter study, we will recruit 400 patients 40 years of age or older at 15 centers with a diagnosis of smoldering multiple myeloma (SMM), a group of patients for whom standard of care is observation not treatment. The main goal of this study is to screen for the diagnosis of light-chain amyloidosis (AL) before the onset of symptomatic disease and to develop a training set for a likelihood algorithm.
Primary Outcome
With a 15-center network covering 12 states and almost 45% of the US population, we will evaluate 400 SMM patients \> 40 years old who pass FLC criteria using standard of care tests including NT-proBNP and clinical marrow specimens evaluated for the presence of t(11;14) and gain1q. Marrow cells will be processed by NGS for clonal IGLV gene identification. With the training data obtained, we will use existing statistical modeling techniques to generate a statistical algorithm for identifying undi
Conditions Studied
Study Locations (13)
California
- Cedars-Sinai Medical Center - Los Angeles
- University of California, San Francisco - San Francisco
New York
- Columbia University Irving Medical Center - New York
- Memorial Sloan Kettering Cancer Center - New York
North Carolina
- Atrium Health Levine Cancer Institute - Charlotte
- UNC Lineberger Comprehensive Cancer Center - Durham
Alabama
- University of Alabama Hospital - Birmingham
Florida
- Cleveland Clinic Florida, Weston Hospital - Weston
Massachusetts
- Tufts Medical Center - Boston
Ohio
- The Ohio State University Comprehensive Cancer Center - Columbus
Texas
- UT Southwestern, Harold C. Simmons Comprehensive Cancer Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2024-05-01 |
| Est. Completion | 2029-02-27 |
What NCT06365060 shows while recruiting
NCT06365060 is an observational study that tracks outcomes without assigning an intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, below the 780-participant average among 20 other Smoldering Multiple Myeloma trials with a reported enrollment target (49% lower).
The record links to 1 condition, with Smoldering Multiple Myeloma appearing as the primary indexed condition, and to 0 interventions.
NCT06365060 lists 13 locations in 10 states (California, New York, North Carolina).
Frequently Asked Questions
What is clinical trial NCT06365060 about?
NCT06365060 is a clinical study titled "Screening for AL Amyloidosis in Smoldering Multiple Myeloma". In this multicenter study, we will recruit 400 patients 40 years of age or older at 15 centers with a diagnosis of smoldering multiple myeloma (SMM), a group of patients for whom standard of care is observation not treatment. The main goal of this study is to screen for the diagnosis of light-chain ...
What is the current status of trial NCT06365060?
This trial is currently recruiting. The enrollment target is 400 participants. The study started on 2024-05-01. Estimated completion is 2029-02-27.
What conditions does trial NCT06365060 study?
This clinical trial studies the following conditions: Smoldering Multiple Myeloma.
Who is sponsoring clinical trial NCT06365060?
This trial is sponsored by Tufts Medical Center, which has 169 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06365060 being conducted?
This trial has 13 study locations across Alabama, California, Florida, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoldering Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06365060's enrollment target sits among peer trials
400 6th of 20 higher than 15 of 20 other Smoldering Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Smoldering Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
RECRUITING · Phase 2
-
Smoldering Myeloma High-Risk Patient Observation and Longitudinal Insight Trial
RECRUITING
-
Registry for Adults With Plasma Cell Disorders (PCD's)
RECRUITING
-
Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma
RECRUITING · Phase 2
-
A Study Comparing a Plant-Based Diet With Supplements and Placebo in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)
RECRUITING · NA
-
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02250352 · 400 participants
Core Biopsies for Establishing a Breast Tumor Tissue Repository
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI